Literature DB >> 28432019

Feasibility of mini-tablets as a flexible drug delivery tool.

Biplob Mitra1, Jessica Chang2, Sy-Juen Wu3, Chad N Wolfe3, Robert L Ternik3, Thomas Z Gunter3, Michael C Victor3.   

Abstract

Mini-tablets have potential applications as a flexible drug delivery tool in addition to their generally perceived use as multi-particulates. That is, mini-tablets could provide flexibility in dose finding studies and/or allow for combination therapies in the clinic. Moreover, mini-tablets with well controlled quality attributes could be a prudent choice for administering solid dosage forms as a single unit or composite of multiple mini-tablets in patient populations with swallowing difficulties (e.g., pediatric and geriatric populations). This work demonstrated drug substance particle size and concentration ranges that achieve acceptable mini-tablet quality attributes for use as a single or composite dosage unit. Immediate release and orally disintegrating mini-tablet formulations with 30μm to 350μm (particle size d90) acetaminophen and Compap™ L (90% acetaminophen) at concentrations equivalent to 6.7% and 26.7% acetaminophen were evaluated. Mini-tablets achieved acceptable weight variability, tensile strength, friability, and disintegration time at a reasonable solid fraction for each formulation. The content uniformity was acceptable for mini-tablets of 6.7% formulations with ≤170μm drug substance, mini-tablets of all 26.7% formulations, and composite dosage units containing five or more mini-tablets of any formulation. Results supported the manufacturing feasibility of quality mini-tablets, and their applicability as a flexible drug delivery tool.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Content uniformity; Dose flexibility; Drug delivery tool; Fixed dose combination; Mini-tablets; Orally disintegrating mini-tablets; Physico-mechanical attributes

Mesh:

Substances:

Year:  2017        PMID: 28432019     DOI: 10.1016/j.ijpharm.2017.04.037

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use.

Authors:  Ousama Rachid; Mutasem Rawas-Qalaji; Keith J Simons
Journal:  Pharmaceutics       Date:  2018-02-11       Impact factor: 6.321

2.  Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised Medication with Tablets.

Authors:  Herman J Woerdenbag; J Carolina Visser; Marlyn P A M Leferink Op Reinink; Roël R van Orsoy; Anko C Eissens; Paul Hagedoorn; Hilda Dijkstra; Derk P Allersma; Shi W Ng; Oscar S N M Smeets; Henderik W Frijlink
Journal:  Pharmaceutics       Date:  2022-01-28       Impact factor: 6.321

3.  Assessment of Mini-Tablets Coating Uniformity as a Function of Fluid Bed Coater Inlet Conditions.

Authors:  Magdalena Turk; Rok Šibanc; Rok Dreu; Maja Frankiewicz; Małgorzata Sznitowska
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321

Review 4.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

5.  Swallowability of Minitablets among Children Aged 6-23 Months: An Exploratory, Randomized Crossover Study.

Authors:  Nao Mitsui; Noriko Hida; Taro Kamiya; Taigi Yamazaki; Kazuki Miyazaki; Kiyomi Saito; Jumpei Saito; Akimasa Yamatani; Yoichi Ishikawa; Hidefumi Nakamura; Akihiro Nakamura; Tsutomu Harada
Journal:  Pharmaceutics       Date:  2022-01-15       Impact factor: 6.321

6.  Implementing the Design of Experiments (DoE) Concept into the Development Phase of Orodispersible Minitablets (ODMTs) Containing Melatonin.

Authors:  Arkadiusz Hejduk; Michał Teżyk; Emilia Jakubowska; Klaudia Krüger; Janina Lulek
Journal:  AAPS PharmSciTech       Date:  2022-01-20       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.